Skip to main content

Advertisement

SpringerLink
Log in

Stable Angina Pectoris

  • Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The stable coronary artery disease (SCAD) population is a heterogeneous group of patients both for clinical presentations and for different underlying mechanisms. The recent European Society of Cardiology guidelines extensively review SCAD from its definition to patients’ diagnostic and therapeutic management. In this review, we deal with five topics that, in our opinion, represent the most intriguing, novel and/or clinically relevant aspects of this complex coronary condition. Firstly, we deal with a peculiar SCAD population: patients with angina and ‘normal’ coronary arteries. Secondly, we reinforce the clinical importance of a diagnostic approach based on the pretest probability of disease. Thirdly, we review and critically discuss the novel pharmacological therapies for SCAD patients. Finally, we analyse the results of the most recent clinical trials comparing revascularization versus optimal medical therapy in SCAD patients and review the currently recommended use of intracoronary functional evaluation of stenosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi:10.1093/eurheartj/eht296. The recent ESC guidelines provide a comprehensive and updated overview of contemporary management in patients with known or suspected SCAD.

    Article  PubMed  Google Scholar 

  2. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.

    Article  CAS  PubMed  Google Scholar 

  3. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42:1161–70.

    Article  PubMed  Google Scholar 

  4. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849–57.

    Article  CAS  PubMed  Google Scholar 

  5. Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kaab S, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J. 2012;33:2831–40.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Proudfit WL, Shirey EK, Sones Jr FM. Selective cine coronary arteriography. Correlation with clinical findings in 1,000 patients. Circulation. 1966;33:901–10.

    Article  CAS  PubMed  Google Scholar 

  7. Patel MR, Peterson ED, Dai D, Brennan JM, Redberg RF, Anderson HV, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362:886–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Collste O, Sörensson P, Frick M, Agewall S, Daniel M, Henareh L, et al. Myocardial infarction with normal coronary arteries is common and associated with normal findings on cardiovascular magnetic resonance imaging: results from the Stockholm Myocardial Infarction with Normal Coronaries study. J Intern Med. 2013;273(2):189–96.

    Article  CAS  PubMed  Google Scholar 

  9. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010;121:2317–25.

    Article  PubMed  Google Scholar 

  10. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830–40.

    Article  CAS  PubMed  Google Scholar 

  11. Ong P, Athanasiadis A, Mahrholdt H, Borgulya G, Sechtem U, Kaski JC. Increased coronary vasoconstrictor response to acetylcholine in women with chest pain and normal coronary arteriograms (cardiac syndrome X). Clin Res Cardiol. 2012;101(8):673–81.

    Article  CAS  PubMed  Google Scholar 

  12. Prinzmetal M, Kennamer R, Merliss R, Wada T, Bor N. Angina pectoris. I. A variant form of angina pectoris; preliminary report. Am J Med. 1959;27:375–88.

    Article  CAS  PubMed  Google Scholar 

  13. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008) – digest version –. Circ J. 2010;74:1745–62.

    Article  Google Scholar 

  14. Takagi Y, Yasuda S, Takahashi J, Tsunoda R, Ogata Y, Seki A, et al. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmic complications, and prognostic impact: multicentre registry study of the Japanese Coronary Spasm Association. Eur Heart J. 2013;34:258–67.

    Article  CAS  PubMed  Google Scholar 

  15. Sueda S, Saeki H, Otani T, Mineoi K, Kondou T, Yano K, et al. Major complications during spasm provocation tests with an intracoronary injection of acetylcholine. Am J Cardiol. 2000;85:391–4.

    Article  CAS  PubMed  Google Scholar 

  16. Buxton A, Goldberg S, Hirshfeld JW, Wilson J, Mann T, Williams DO, et al. Refractory ergonovine-induced coronary vasospasm: importance of intracoronary nitroglycerin. Am J Cardiol. 1980;46:329–34.

    Article  CAS  PubMed  Google Scholar 

  17. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation. 2003;107:149–58.

    Article  PubMed  Google Scholar 

  18. Genders TS, Meijboom WB, Meijs MF, Schuijf JD, Mollet NR, Weustink AC, et al. CT coronary angiography in patients suspected of having coronary artery disease: decision making from various perspectives in the face of uncertainty. Radiology. 2009;253:734–44.

    Article  PubMed  Google Scholar 

  19. Perk J, De Backer G, Gohlke H. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012;19(4):585–667.

  20. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967–74.

    Article  PubMed  Google Scholar 

  21. IARC. IARC handbooks of cancer prevention. Vol.11, Tobacco control: reversal of risk after quitting smoking. Lyon: IARC; 2007.

  22. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;1, CD003041.

    PubMed  Google Scholar 

  23. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–81.

    Article  PubMed  Google Scholar 

  24. Davies RF, Habibi H, Klinke WP, Dessain P, Nadeau C, Phaneuf DC, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol. 1995;25:619–25.

    Article  CAS  PubMed  Google Scholar 

  25. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

    Article  Google Scholar 

  26. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Doubleblind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340:1421–5.

    Article  CAS  PubMed  Google Scholar 

  27. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.

    Article  PubMed  Google Scholar 

  28. Opie LH, Horowitz JD. Nitrates and newer antianginals. In: Opie LH, Gersh BJ, editors. Drugs for the heart. 8th ed. Amsterdam: Elsevier; 2012.

    Google Scholar 

  29. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359:1269–75.

    Article  Google Scholar 

  30. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–36.

    Article  CAS  PubMed  Google Scholar 

  31. Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012;126:1858–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 1993;72:1249–56.

    Article  CAS  PubMed  Google Scholar 

  33. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775–83.

    Article  CAS  PubMed  Google Scholar 

  35. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119:2032–9.

    Article  CAS  PubMed  Google Scholar 

  36. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-segment Elevation Acute Coronary Syndromes) 36 trial. J Am Coll Cardiol. 2009;53:1510–6.

    Article  CAS  PubMed  Google Scholar 

  37. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817–21.

    Article  PubMed  Google Scholar 

  38. Joannides R, Moore N, Iacob M, et al. Comparative effects of ivabradine, a selective HR-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61:127–37.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers HR but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149–55.

    Article  CAS  PubMed  Google Scholar 

  40. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D. 2003;4:83–9.

    Article  CAS  PubMed  Google Scholar 

  41. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–23.

    Article  PubMed  Google Scholar 

  42. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45:469–91.

    Article  CAS  PubMed  Google Scholar 

  43. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27:42–8.

    Article  CAS  PubMed  Google Scholar 

  44. Ranexa (ranolazine). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Summary_for_the_public/human/000805/WC500045940.pdf. Accessed 23 Aug 2013.

  45. Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina. Results from the TERISA randomized clinical trial. J Am Coll Cardiol. 2013;61(20):2038–45.

    Article  CAS  PubMed  Google Scholar 

  46. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.

    Article  CAS  PubMed  Google Scholar 

  47. de Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001. FAME 2 mimicked the COURAGE trial design with the addition of FFR evaluation. The study was stopped prematurely by the Data Safety Monitoring Board, owing to a highly significant reduction in the rates of hospital readmission and urgent revascularization in the FFR ≤ 0.80 PCI group.

    Article  PubMed  Google Scholar 

  48. Dagenais GR, Lu J, Faxon DP, Kent K, Lago RM, Lezama C, et al. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation. 2011;123:1492–500.

    Article  PubMed  Google Scholar 

  49. Boden WE, O’Rourke RA, Teo KK, et al. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006;151:1173–9.

    Article  CAS  PubMed  Google Scholar 

  50. Califf RM, Armstrong PW, Carver JR, D’Agostino RB, Strauss WE. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol. 1996;27:1007–19.

    Article  CAS  PubMed  Google Scholar 

  51. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van’t Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER study. J Am Coll Cardiol. 2007;49:2105–11.

    Article  PubMed  Google Scholar 

  52. Pijls NH, Sels JW. Functional measurement of coronary stenosis. J Am Coll Cardiol. 2012;59:1045–57.

    Article  PubMed  Google Scholar 

  53. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501–55.

    Article  PubMed  Google Scholar 

  54. Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56(3):177–84. doi:10.1016/j.jacc.2010.04.012.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Marco Valgimigli and Simone Biscaglia declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Thoraxcenter, BA 587, Erasmus MC, Rotterdam, The Netherlands

    Marco Valgimigli

  2. Cardiology Department, University of Ferrara, Ferrara, Italy

    Simone Biscaglia

Authors
  1. Marco Valgimigli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simone Biscaglia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Valgimigli.

Additional information

This article is part of the Topical Collection on Cardiovascular Disease and Stroke

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Valgimigli, M., Biscaglia, S. Stable Angina Pectoris. Curr Atheroscler Rep 16, 422 (2014). https://doi.org/10.1007/s11883-014-0422-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-014-0422-4

Keywords

Search

Navigation